Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Enterprise Value (2016 - 2025)

Ironwood Pharmaceuticals' Enterprise Value history spans 17 years, with the latest figure at -$215.5 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 143.29% year-over-year to -$215.5 million; the TTM value through Dec 2025 reached -$215.5 million, down 143.29%, while the annual FY2025 figure was -$215.5 million, 143.29% down from the prior year.
  • Enterprise Value for Q4 2025 was -$215.5 million at Ironwood Pharmaceuticals, down from -$140.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$88.2 million in Q3 2024 and bottomed at -$741.6 million in Q1 2023.
  • The 5-year median for Enterprise Value is -$196.3 million (2023), against an average of -$327.8 million.
  • The largest annual shift saw Enterprise Value soared 85.98% in 2023 before it plummeted 143.29% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$621.4 million in 2021, then fell by 5.81% to -$657.5 million in 2022, then skyrocketed by 85.98% to -$92.2 million in 2023, then increased by 3.9% to -$88.6 million in 2024, then plummeted by 143.29% to -$215.5 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Enterprise Value are -$215.5 million (Q4 2025), -$140.4 million (Q3 2025), and -$92.9 million (Q2 2025).